Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.

珍妮丝·M Mehnert，医学博士，是临床研究副主任（AD），主任，黑色素瘤和 皮肤肿瘤学和纽约大学Perlmutter癌症中心（PCC）的终身医学教授 Langone Health/纽约大学格罗斯曼医学院。在这里，她做出了重大努力， NCI申办的临床研究。她活跃于NCI赞助的临床试验网络，包括 国家临床试验网络（NCTN），她在那里担任东部肿瘤合作组织（Eastern Cooperative Oncology） 美国放射学成像网络学会（ECOG-ACRIN）黑色素瘤和皮肤委员会 联合主席和早期治疗药物临床试验网络（ET-CTN），她担任研究中心PI 监督PCC的ET-CTN临床试验工作。她进行并发表了多项研究， 启动了协议，其中许多得到了NCI的支持，并展示了指导初级调查员的记录。 作为AD，Mehnert博士负责监督曼哈顿、长岛（LI）、 和贝尔维尤医院中心（监督研究中心医学总监和临床试验办公室（CTO）行政 董事和工作人员），CTO资源分配，PCC的研究方案的优先次序和PCC的监督 12个疾病管理小组（DMG）。她还完成了未来临床研究的战略规划 活动，包括那些在PCC的布鲁克林校园。自从她被招募到PCC，她带头 重组临床研究基础设施，缩短试验启动时间， 支持PCC-LI的I期试验活动。她让PCC参与NCI赞助的倡议， 公平地进行临床试验。她成功地为创建访问目标的资金竞争， 癌症治疗服务不足的人群（追赶）计划，这使她能够迅速激活20 ET-CTN试验和组装一个预筛选基础设施，以导航种族和民族多样性， 接受ET-CTN方案治疗的患者。她随后领导了PCC融入Dana 法伯-哈佛癌症中心领导学术组织（UM 1CA 186709）作为附属组织。 在这份申请中，她概述了以下计划：1）促进PCC调查人员领导NCI的机会- 申办的临床试验; 2）促进NCI申办的试验的累积，包括提交NCTN 牵头学术参与研究中心（LAPS）补助金，3）促进公平获得临床试验，以及4） 促进公平获得研究机会。她还概述了改善沟通的计划 试验产品，增加精准医学试验的可及性，并开发信息技术 简化研究过程的方法。R50临床研究专家奖将允许PCC 保护梅纳特博士进行这些研究的时间她对这些目标的实现将增加 PCC研究者和PCC患者获得NCI申办的试验和临床研究机会， 对PCC临床研究企业和NCI临床研究使命的重大奖励。

Janice M. Mehnert, M.D., is the Associate Director (AD) for Clinical Research, Director, Melanoma and Cutaneous Oncology and a tenured Professor of Medicine at the Perlmutter Cancer Center (PCC) of NYU Langone Health/NYU Grossman School of Medicine. Here, she engages in significant efforts to promote NCI-sponsored clinical research. She is active within NCI sponsored clinical trials networks, including the National Clinical Trials Network (NCTN), where she serves as the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Melanoma and Skin Committee Co-Chair, and the Early Therapeutics Clinical Trials Network (ET-CTN), where she serves as site PI overseeing PCC’s ET-CTN clinical trial efforts. She has conducted and published multiple investigator initiated protocols, many with NCI support, and demonstrated a track record of mentoring junior investigators. As AD, Dr. Mehnert is responsible for the supervision of clinical trial operations in Manhattan, Long Island (LI), and Bellevue Hospital Center (overseeing site Medical Directors and Clinical Trials Office (CTO) Administrative Directors and staff), CTO resource allocation, prioritization of PCC’s research protocols and oversight of PCC’s 12 Disease Management Groups (DMGs). She also completes strategic planning for future clinical research activities including those at PCC’s Brooklyn campus. Since her recruitment to PCC, she has spearheaded the reorganization of the clinical research infrastructure, decreased trial activation timelines, and assembled resources to support Phase I trial activity at PCC-LI. She engaged PCC in NCI-sponsored initiatives to promote equitable access to clinical trials. She successfully competed for funding for the Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP) Program, which allowed her to rapidly activate 20 ET-CTN trials and assemble a prescreening infrastructure to navigate racially and ethnically diverse and underserved patients to ET-CTN protocols. She subsequently led the integration of PCC into the Dana Farber-Harvard Cancer Center Lead Academic Organization (UM1CA186709) as an Affiliate Organization. In this application, she outlines plans to 1) Promote opportunities for PCC investigators to lead NCI- sponsored clinical trials; 2) Promote accrual to NCI sponsored trials, including the submission of a NCTN Lead Academic Participating Site (LAPS) grant, 3) Promote equitable access to clinical trials and 4) Promote equitable access to research opportunities. She also outlines plans to improve communication of trial offerings, increase access to precision medicine trials, and develop information technology approaches to streamline research processes. The R50 Clinical Research Specialist Award would allow PCC to protect Dr. Mehnert’s time to pursue these research activities. Her accomplishment of these goals will increase access for PCC investigators and PCC patients to NCI sponsored trials and clinical research opportunities, a significant reward for the PCC clinical research enterprise and the NCI clinical research mission.